Therapeutic Area | MeSH |
---|---|
urogenital diseases | D000091642 |
signs and symptoms pathological conditions | D013568 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
ORTHO CYCLEN-21 | Johnson & Johnson | N-019653 DISCN | 1989-12-29 | 1 products |
ORTHO CYCLEN-28 | Johnson & Johnson | N-019653 DISCN | 1989-12-29 | 1 products, RLD |
ORTHO TRI-CYCLEN | Johnson & Johnson | N-019697 DISCN | 1992-07-03 | 2 products |
ORTHO TRI-CYCLEN LO | Johnson & Johnson | N-021241 DISCN | 2002-08-22 | 1 products, RLD |
Brand Name | Status | Last Update |
---|---|---|
estarylla | ANDA | 2024-10-01 |
femynor | ANDA | 2020-12-29 |
mili | ANDA | 2024-12-07 |
mono-linyah | ANDA | 2025-01-20 |
mononessa | New Drug Application | 2019-01-09 |
norgestimate and ethinyl estradiol | ANDA | 2025-05-28 |
nymyo | ANDA | 2022-12-08 |
ortho tri cyclen | New Drug Application | 2012-02-27 |
ortho tri cyclen lo | New Drug Application | 2011-02-03 |
ortho tri-cyclen lo | New Drug Application | 2009-12-31 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Contraception | D003267 | — | — | 3 | 1 | 2 | 2 | 2 | 10 |
Contraception behavior | D003268 | — | — | 1 | — | — | 1 | 1 | 3 |
Insulin resistance | D007333 | EFO_0002614 | E88.819 | — | 1 | — | 1 | — | 2 |
Acne vulgaris | D000152 | EFO_0003894 | L70 | — | — | — | 2 | — | 2 |
Heart disease risk factors | D000082742 | — | — | — | — | — | 1 | — | 1 |
Glucose intolerance | D018149 | HP_0000833 | R73.03 | — | — | — | 1 | — | 1 |
Perimenopause | D047648 | — | — | — | — | — | 1 | — | 1 |
Hemorrhage | D006470 | MP_0001914 | R58 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Primary ovarian insufficiency | D016649 | EFO_0004266 | E28.3 | — | — | 1 | — | — | 1 |
Premature menopause | D008594 | — | E28.31 | — | — | 1 | — | — | 1 |
Ovarian cysts | D010048 | — | N83.1 | — | 1 | 1 | — | — | 1 |
Cysts | D003560 | — | — | — | 1 | 1 | — | — | 1 |
Congenital abnormalities | D000013 | EFO_0003915 | Q89.9 | — | — | 1 | — | — | 1 |
Nervous system diseases | D009422 | — | G00-G99 | — | — | 1 | — | — | 1 |
Hereditary congenital and neonatal diseases and abnormalities | D009358 | — | — | — | — | 1 | — | — | 1 |
Neural tube defects | D009436 | — | Q00.0 | — | — | 1 | — | — | 1 |
Nervous system malformations | D009421 | — | Q00-Q07 | — | — | 1 | — | — | 1 |
Spinal dysraphism | D016135 | EFO_1001210 | Q05 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Thrombosis | D013927 | — | — | — | 1 | — | — | 1 | 2 |
Inflammation | D007249 | MP_0001845 | — | — | 1 | — | — | — | 1 |
Metrorrhagia | D008796 | — | N92.1 | — | 1 | — | — | — | 1 |
Osteoporosis | D010024 | EFO_0003882 | M81.0 | — | 1 | — | — | — | 1 |
Anorexia nervosa | D000856 | EFO_0004215 | F50.0 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 8 | — | — | — | — | 8 |
Pharmacokinetics | D010599 | — | — | 6 | — | — | — | — | 6 |
Hepatitis c | D006526 | — | B19.2 | 3 | — | — | — | — | 3 |
Hiv infections | D015658 | EFO_0000764 | B20 | 2 | — | — | — | — | 2 |
Infections | D007239 | EFO_0000544 | — | 2 | — | — | — | — | 2 |
Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 2 | — | — | — | — | 2 |
Drug interactions | D004347 | — | — | 2 | — | — | — | — | 2 |
Therapeutic equivalency | D013810 | — | — | 2 | — | — | — | — | 2 |
Pregnancy rate | D018873 | — | — | 1 | — | — | — | — | 1 |
Pregnancy | D011247 | EFO_0002950 | Z33.1 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Venous thrombosis | D020246 | — | I82.40 | — | — | — | — | 1 | 1 |
Venous thromboembolism | D054556 | EFO_0004286 | I74 | — | — | — | — | 1 | 1 |
Myocardial infarction | D009203 | EFO_0000612 | I21 | — | — | — | — | 1 | 1 |
Thromboembolism | D013923 | — | — | — | — | — | — | 1 | 1 |
Infarction | D007238 | EFO_0009463 | — | — | — | — | — | 1 | 1 |
Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | — | 1 | 1 |
Body weight | D001835 | EFO_0004338 | — | — | — | — | — | 1 | 1 |
Overweight | D050177 | — | E66.3 | — | — | — | — | 1 | 1 |
Body weight changes | D001836 | — | — | — | — | — | — | 1 | 1 |
Appetitive behavior | D001070 | — | — | — | — | — | — | 1 | 1 |
Drug common name | Norgestimate |
INN | norgestimate |
Description | Norgestimate is a steroid ester, a ketoxime and a terminal acetylenic compound. It has a role as a contraceptive drug, a progestin and a synthetic oral contraceptive. |
Classification | Small molecule |
Drug class | progestins |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | C#C[C@]1(OC(C)=O)CC[C@H]2[C@@H]3CCC4=C/C(=N/O)CC[C@@H]4[C@H]3CC[C@@]21CC |
PDB | — |
CAS-ID | 35189-28-7 |
RxCUI | — |
ChEMBL ID | CHEMBL1200934 |
ChEBI ID | 50815 |
PubChem CID | 6540478 |
DrugBank | DB00957 |
UNII ID | C291HFX4DY (ChemIDplus, GSRS) |